Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.3Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: 1.26%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The call reflects optimism around LUMRYZ's market performance and Avadel's strategic investments to drive growth. Despite legal uncertainties and challenges with patient switches and Q1 financial dynamics, the overall sentiment is positive, driven by strong uptake metrics and financial guidance.Company Guidance
In the recent conference call, Avadel Pharmaceuticals reiterated its guidance for 2025, projecting revenue between $240 million and $260 million, reflecting a near 50% increase over 2024. The company anticipates a 40% rise in patients on therapy and expects cash operating expenses to range from $180 million to $200 million. Avadel has increased its commercial investment, doubling the size of its field support and nursing teams, while expanding its sales force by 15% to enhance engagement with prescribers and patients. Early 2025 trends are tracking at or above internal expectations, with significant growth expected as newly added patients impact revenues in the second quarter and beyond. The company also achieved positive cash flow in Q4 2024, ending the year with $74 million in cash and marketable securities, positioning itself for sustained positive cash flow in 2025.Strong LUMRYZ Uptake
LUMRYZ added over 2,500 net patients, capturing nearly 75% of reported total net patients added in the market since its launch, reflecting strong clinical value and demand.
Positive Financial Performance
Avadel reported net revenue of $50.4 million for Q4 2024, with a gross profit of $45.6 million, marking the second consecutive quarter of positive adjusted operating income.
Increased Commercial Investments
Strategic investments in expanding customer-facing teams and enhancing commercial leadership, including hiring industry veterans, are expected to accelerate LUMRYZ's growth.
Encouraging Patient Trends and Revenue Guidance
Early 2025 trends point to favorable patient demand metrics, with revenue projected to increase nearly 50% over 2024, and cash flow expected to be positive in the range of $20 million to $40 million.
Advancements in Life Cycle Management
Enrollment in the Phase III REVITALYZ trial for idiopathic hypersomnia is progressing on track, with potential NDA filing expected post-topline data in early 2026.
---
AVDL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AVDL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $7.91 | $7.55 | -4.55% |
| Nov 12, 2024 | $16.30 | $13.15 | -19.33% |
| Aug 08, 2024 | $16.10 | $15.74 | -2.24% |
| May 08, 2024 | $18.18 | $16.25 | -10.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Avadel Pharmaceuticals (AVDL) report earnings?
Avadel Pharmaceuticals (AVDL) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Avadel Pharmaceuticals (AVDL) earnings time?
Avadel Pharmaceuticals (AVDL) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVDL EPS forecast?
AVDL EPS forecast for the fiscal quarter 2025 (Q1) is -0.06.
---